Some patients and doctors are calling on the FDA to formally recognize a shortage of the medications, saying the agency's shortage database does not reflect problems they are seeing at pharmacies.
Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.
FDA begins review of experimental injectable peptides FDA reviews seven experimental injectable peptides for pharmacy dispensing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results